A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF REZAFUNGIN FOR INJECTION VERSUS THE STANDARD ANTIMICROBIAL REGIMEN TO PREVENT INVASIVE FUNGAL DISEASES IN ADULTS UNDERGOING ALLOGENEIC BLOOD AND MARROW TRANSPLANTATION (THE RESPECT STUDY)
- Registry ID
- CD101.IV.3.08
- Source registry
- HEALTH_CANADA
- Status
- Closed
- Phase
- PHASE3
- Study type
- INTERVENTIONAL
- Sponsor
- MUNDIPHARMA RESEARCH LIMITED
- Start date
- 2023-09-11
- Completion date
- 2026-02-09
- Last update
- 2019-11-01
Conditions
Related clinical trials
- A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-BLIND STUDY OF SAFETY AND EFFICACY OF EL219 (TURLETRICIN) VERSUS LIPOSOMAL AMPHOTERICIN B OR VORICONAZOLE FOR EARLY ANTIFUNGAL THERAPY OF INVASIVE MOULD INFECTIONS (TREAT-1)
- AN INTERVENTIONAL PHASE 3, OPEN-LABEL, TWO-COHORT STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF FOSMANOGEPIX IN ADULT PATIENTS WITH INVASIVE MOLD INFECTIONS CAUSED BY ASPERGILLUS SPP., FUSARIUM SPP., LOMENTOSPORA PROLIFICANS, MUCORALES FUNGI, OR OTHER MULTI-DRUG RESISTANT MOLDS
- A PHASE III, ADJUDICATOR-BLINDED, RANDOMISED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TREATMENT WITH OLOROFIM VERSUS TREATMENT WITH AMBISOME® FOLLOWED BY STANDARD OF CARE (SOC) IN PATIENTS WITH INVASIVE FUNGAL DISEASE (IFD) CAUSED BY ASPERGILLUS SPECIES
View on source registry